What Happened? A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as ...

Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look ...

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected ...

Moderna beat analysts’ revenue expectations by 10.7% last quarter, reporting revenues of $142 million, down 41.1% year on ...

Collaboration combines leading technologies to develop breakthrough, mRNA-enabled in vivo expressed TCER® molecules Companies to leverage Immatics’ XPRESIDENT® target discovery platform and Moderna’s ...

Telemark Asset Management, LLC established a new position in Moderna ( MRNA +1.10%), acquiring 500,000 shares valued at approximately $12.91 million as of September 30, 2025, according to a November ...

Novartis launched a tender offer for Regulus Therapeutics. Biogen and City Therapeutics announced a partnership to develop a drug for an undisclosed central nervous system disease. Eli Lilly bought ...

Learn more about whether Moderna, Inc. or Viridian Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Although Congress remains stalled on funding to combat the Zika virus, the Biomedical Advanced Research and Development Authority (BARDA) has taken steps to accelerate US preparedness and response ...

SEATTLE--(BUSINESS WIRE)--Today, Amazon Web Services, Inc. (AWS), an Amazon.com company (NASDAQ: AMZN), announced that Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering a new class of ...

The nucleic acid therapeutics market is growing due to rising genetic and chronic disease prevalence, expanding genomics R&D, ...